190 related articles for article (PubMed ID: 18640165)
21. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO
Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967
[TBL] [Abstract][Full Text] [Related]
22. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO
Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785
[TBL] [Abstract][Full Text] [Related]
23. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
24. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
25. Impact of minimal tumor burden on antibody response to vaccination.
Kim SK; Wu X; Ragupathi G; Gathuru J; Koide F; Cheung NK; Panageas K; Livingston PO
Cancer Immunol Immunother; 2011 May; 60(5):621-7. PubMed ID: 21267719
[TBL] [Abstract][Full Text] [Related]
26. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
28. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
29. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.
Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877
[TBL] [Abstract][Full Text] [Related]
30. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
31. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
32. Cellular and humoral adjuvant activity of lectins isolated from Korean mistletoe (Viscum album colaratum).
Yoon TJ; Yoo YC; Kang TB; Her E; Kim SH; Kim K; Azuma I; Kim JB
Int Immunopharmacol; 2001 May; 1(5):881-9. PubMed ID: 11379043
[TBL] [Abstract][Full Text] [Related]
33. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
34. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulating activity of Echinacea gloriosa L., Echinacea angustifolia DC. and Rudbeckia speciosa Wenderoth ethanol-water extracts.
Bukovský M; Vaverková S; Kost'álová D
Pol J Pharmacol; 1995; 47(2):175-7. PubMed ID: 8688891
[TBL] [Abstract][Full Text] [Related]
36. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
Krug LM; Ragupathi G; Hood C; Kris MG; Miller VA; Allen JR; Keding SJ; Danishefsky SJ; Gomez J; Tyson L; Pizzo B; Baez V; Livingston PO
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6094-100. PubMed ID: 15447995
[TBL] [Abstract][Full Text] [Related]
37. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.
Stahl-Hennig C; Eisenblätter M; Jasny E; Rzehak T; Tenner-Racz K; Trumpfheller C; Salazar AM; Uberla K; Nieto K; Kleinschmidt J; Schulte R; Gissmann L; Müller M; Sacher A; Racz P; Steinman RM; Uguccioni M; Ignatius R
PLoS Pathog; 2009 Apr; 5(4):e1000373. PubMed ID: 19360120
[TBL] [Abstract][Full Text] [Related]
38. Carbohydrate antigens as targets for active specific immunotherapy.
Ragupathi G
Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568
[TBL] [Abstract][Full Text] [Related]
39. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
[TBL] [Abstract][Full Text] [Related]
40. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
Aarntzen EH; de Vries IJ; Göertz JH; Beldhuis-Valkis M; Brouwers HM; van de Rakt MW; van der Molen RG; Punt CJ; Adema GJ; Tacken PJ; Joosten I; Jacobs JF
Cancer Immunol Immunother; 2012 Nov; 61(11):2003-11. PubMed ID: 22527252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
